Search

Search Constraints

You searched for: Author/Creator Santaballa, Ana

Search Results

1. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer. Issue 6 (July 2019)

3. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. Issue 4 (April 2022)

4. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. (June 2022)

5. 2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO. (20th October 2022)

6. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. (December 2022)

7. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. (September 2022)

8. GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer. (10th January 2019)

9. Feasibility and Safety of a Modified Outpatient Regimen With Intravenous/Intraperitoneal Chemotherapy for Optimally Debulked Stage III Ovarian Cancer. Issue 2 (1st February 2015)

10. Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer. (November 2020)